Alerts will be sent to your verified email
Verify Email
BETA
|
Beta Drugs
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
22.74 % | 9.79 % | 16.01 % |
|
5yr average Equity Multiplier
|
1.82 | 1.41 | 1.27 |
|
5yr Average Asset Turnover Ratio
|
1.03 | 0.81 | 1.09 |
|
5yr Avg Net Profit Margin
|
12.23 % | 8.78 % | 12.08 % |
|
Price to Book
|
8.14 | 3.65 | 5.32 |
|
P/E
|
37.85 | 21.89 | 21.72 |
|
5yr Avg Cash Conversion Cycle
|
7.75 Days | 61.57 Days | 2.39 Days |
|
Inventory Days
|
46.07 Days | 27.32 Days | 37.29 Days |
|
Days Receivable
|
91.57 Days | 82.75 Days | 15.63 Days |
|
Days Payable
|
119.03 Days | 79.41 Days | 59.94 Days |
|
5yr Average Interest Coverage Ratio
|
14.42 | 31.44 | 66.99 |
|
5yr Avg ROCE
|
27.84 % | 13.63 % | 18.99 % |
|
5yr Avg Operating Profit Margin
|
21.76 % | 9.97 % | 13.23 % |
|
5 yr average Debt to Equity
|
0.29 | 0.19 | 0.01 |
|
5yr CAGR Net Profit
|
29.34 % | 36.24 % | 26.54 % |
|
5yr Average Return on Assets
|
12.69 % | 7.11 % | 12.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.73 % | 50.57 % | 67.54 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.02 % | 0.0 | -1.18 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Beta Drugs
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|